Kenneth Peters, MD
16
0
0
12
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 65/100
25.0%
4 terminated/withdrawn out of 16 trials
75.0%
-11.5% vs industry average
0%
0 trials in Phase 3/4
58%
7 of 12 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (16)
InterStim Prospective Database
Role: lead
Prostatectomy Prospective Database
Role: lead
Prospective Trial Comparing Response to Hyperbaric Oxygen Treatment in Patients With Interstitial Cystitis
Role: lead
Intravesical Liposomes for Ulcerative Cystitis
Role: lead
Intravesical Liposomes for Interstitial Cystitis/Painful Bladder Syndrome (IC/PBS)
Role: lead
Autologous Stem Cells for Urinary Incontinence: Single Patient Compassionate Use
Role: lead
Utilization of the BIOWAVE Device to Treat Overactive Bladder
Role: lead
Urology Database to Evaluate Clinical Information and Improve Patient Care.
Role: lead
Pelvic Floor Physical Therapy-Biomarkers Project
Role: lead
Lumbar to Sacral Ventral Nerve Re-Routing
Role: lead
CC-10004 For The Treatment Of Vulvodynia
Role: lead
An Open-Label Study of CC-10004 for Chronic Prostatitis/Chronic Pelvic Pain Syndrome
Role: lead
Urology Database for Outcomes Research
Role: lead
Open-Label Study of Thalidomide for Chronic Prostatitis/Chronic Pelvic Pain
Role: lead
Nerve Rerouting Treatment for Neurogenic Bladder in Spina Bifida
Role: lead
Impact Of Sacral Neuromodulation On Urine Markers For Interstitial Cystitis (IC)
Role: lead
All 16 trials loaded